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Human Papillomavirus Status in Head and
Neck Cancer
The Ethics of Disclosure
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Human papillomavirus (HPV) is an emerging causative factor for squamous carcinoma of the oropharynx and perhaps
other head and neck cancers. There is a great deal of uncertainty regarding the clinical significance and implications
of HPV status in this patient population. As a result, there is no established protocol for informing patients of the
potential link between viral infection and their cancer. This paper discusses some of the ethical issues involved with
informing head and neck cancer patients of their HPV status, recognizing the dilemma posed by unresolved clinical
questions and the need to respect the autonomy of patients by disclosing relevant information. Cancer
2010;116:4221–6. VC 2010 American Cancer Society.
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An increasing volume of data have linked infection with human papillomavirus (HPV), a sexually transmitted pathogen,
with head and neck cancer.1,2 HPV infection may explain the increasing incidence and changing demographics of these
cancers, particularly squamous cell carcinomas of the oropharynx.3,4 Patients with HPV-related tumors often lack the clas-
sic risk factors for these malignancies, such as a history of tobacco or alcohol abuse, and often present at younger ages.5
Currently, there are no conclusive data suggesting that treatment modalities or other aspects of care should differ for head
and neck cancer patients based on their HPV status.
The issue of discussing the relationship of HPV status and the development of head and neck cancer poses a
dilemma. Clinicians aspire to keep their patients duly informed, but may not know which patients might have HPV-
related infections, nor can they make further definitive statements regarding etiology or outcome based on the limited
knowledge of this clinical entity. In general, we know that the association of HPV infection in a nonsmoking head and
neck cancer patient is a favorable prognostic factor; however, the literature addressing HPV-related head and neck cancers
is growing exponentially. This paper does not attempt to provide a comprehensive review of the topic, but will discuss the
ethical issues surrounding the disclosure and discussion of HPV status among head and neck cancer patients.
Ethical Tenets of Honesty and Transparency
Contemporary medical ethics is based on a foundation in which patients and their healthcare providers are partners.
Patients and their designated decision-makers are charged with using the expertise and recommendations of their physi-
cians to make informed and reasoned decisions. Rather than make paternalistic judgments concerning what patients
should know or must do, physicians are obligated to present all relevant and pertinent information in a way that is accurate
and honest, and allow their patients to act autonomously. One model of this process involves the implementation of both
informal conversational ethics and formal deliberative ethics.6 The former process centers on the creation of a partnership
between physician and patient that fosters open lines of communication, honesty, and discussion. The latter involves care-
ful deliberation of choices, alternatives, and outcomes, taking both the clinician’s and the patient’s input and assimilating
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them into a workable solution that is both practical and in
accordance with the patient’s preferences. In reality, these
2 processes are cohesive and frequently occur simultane-
ously, but the model highlights the importance of the
physician-patient relationship itself, which must exist
before specific decisions are approached.
Uncertainty of HPV Status
Many patients and physicians will not know conclusively
whether a specific cancer is related to prior HPV infec-
tion. Although a sexual history, demographic factors such
as age, and the presence or absence of comorbid behaviors
(alcohol and tobacco abuse) may help predict HPV status,
they are by no means foolproof.7 Identification of molec-
ular biomarkers for HPV and/or immunohistological
staining of tumor specimens for p16 are effective methods
of determining HPV status.8 However, this information
currently does not affect the patient’s care or impact treat-
ment decisions other than to suggest a trend with regard
to prognosis, and is not routinely performed at most
institutions.
Given the uncertainty of HPV status in each indi-
vidual patient’s neoplasm, and the finding that HPV
seems most closely related only to oropharyngeal cancers,
do all patients diagnosed with squamous cell carcinoma of
the head and neck deserve to be educated about the virus
and its implications? Physicians can and should be honest
with patients, using patient history and clinical judgment
to shape the conversation. Patients for whom HPV infec-
tion is an exceedingly unlikely prospect (the elderly pipe-
smoking celibate bachelor, for example) may be assured
that they are unlikely to have an HPV-related neoplasm,
but the virus and its role in related neoplasms should still
be discussed. In contrast, a young professional nonsmoker
might appreciate more information, identifying a poten-
tial causative factor for what is likely a devastating and
unexpected diagnosis. As the patient community contin-
ues to receive medical information from sources other
than their healthcare workers, such as other patients,
friends, family members, and the Internet, we are obli-
gated to ensure that patients receive accurate information
and that we dispel inaccuracies. A patient’s right to know
exceeds the need to shield them from the potential psy-
chological stress of an emotionally charged conversation
with their physician.
HPV as a Sexually Transmitted Infection
HPV is a sexually transmitted infection with a high preva-
lence in the general population. In general, orogenital
sexual encounters are considered the etiology of HPV
infections that may contribute to the development of
head and neck cancer.9 As with all other sexually transmit-
ted infections, safer sexual practices may be considered the
mainstay of prevention. The association between HPV
infection and head and neck cancer does not suggest direct
transmissibility of oncogenic infections, and patients with
head and neck cancer are not considered contagious with
regard to their partner’s risk of developing cancer. That
said, a recent study has demonstrated that the odds of con-
tracting oral HPV infection are significantly raised with
progressive increases in the number of oral sexual and
open-mouthed kissing partners.10 Specific HPV genetic
markers have also been indentified among couples in
which both members contracted tonsil cancer, associating
direct viral transmission with cancer in both exposed
parties.11
Despite this information, there is little medical justi-
fication to support counseling newly diagnosed head and
neck cancer patients that they must inform prior sexual
contacts that they have an increased risk for head and neck
cancer, or to suggest that changes in behavior will affect
their or their partner’s future risk of malignancy. Despite
an increased relative risk with certain sexual behaviors,
HPV infections are very common and HPV-related
malignancies are relatively rare, so that the absolute risk,
even for close contacts of infected patients, is much
smaller. Moreover, it is likely that there is considerable
latency between the time of HPV infection and the devel-
opment of cancer, indicative that previous viral infection,
rather than current or future exposures, is the source of
the disease.12 In addition, it behooves physicians counsel-
ing patients to disclose that there is a great deal of uncer-
tainty with regard to HPV’s transmissibility and its
relationship with head and neck cancer, obviating the
ability to make ironclad recommendations.
Sharing information concerning sexually transmit-
ted infections can be difficult for clinicians and patients
alike, even when the facts are more concrete. Current
practices regarding HIV testing and communication of
HIV status may be instructional and bear some similar-
ities with the HPV issue. With regard to disclosure of
HIV test results, patient autonomy drives decision mak-
ing. Although individuals are encouraged to participate in
routine screening, and to share their test status with sexual
contacts, neither is mandatory.13 Some have questioned
whether the rights of sexual partners should trump the
autonomy and confidentiality enjoyed by patients who
either test positive or who refuse testing despite significant
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risk factors.14 Most importantly, HIV testing should be
preceded by in-depth counseling, and all test results
should be delivered concordant with information about
their implications, just as should be the case when discus-
sing HPV.
Patients with suspected HPV-related head and neck
cancer should be educated regarding the sexually trans-
mitted nature of the virus, as well as the uncertainty
concerning epidemiology, health behaviors, and transmis-
sibility. Given the associated risk factors and the Centers
for Disease Control and Prevention (CDC)’s routine rec-
ommendations for human immunodeficiency virus
(HIV) testing, patients with HPV-related tumors should
also be counseled to be tested for HIV.13 As with HIV
testing, knowledge of HPV status requires preparation
and education for patients to understand the context of
the information.
Oncologic Prognosis
Currently, there are no data suggesting that treatment
modalities should differ among patients with head and
neck cancer dependent on their HPV status. Thus, clinical
decision making does not depend on this knowledge, and
is unlikely to fundamentally change the medical or surgi-
cal approach to these patients. However, there are ample
data to suggest that HPV-related cancers are distinct clini-
cal entities, and have different biological behaviors. Multi-
ple studies have confirmed that patients with HPV-
related oropharyngeal cancer have a better prognosis than
patients with tumors not associated with HPV.15,16 To
date, this has not led to any change in the treatment or
staging of these malignancies, and has not been applied to
a systematic method of adjusting prognosis.17 However,
future clinical trials may attempt to decrease the intensity
of treatment in this subset of patients to limit morbidity,
thereby taking advantage of the less aggressive biology of
HPV-related tumors.
The ethics of sharing prognostic information has
been discussed comprehensively in the genetics literature.
With regard to mutations in genes predisposing women
to breast cancer, the ethical issues regard the involvement
and testing of relatives with uncertain risk, as well as the
potential for closer screening exams and even prophylactic
ablative surgery for those carrying the genetic mutation.18
Established guidelines dictate how this process occurs,
ensuring that only appropriate candidates are included,
pretest education and counseling are stressed, results are
shared in a tactful manner, and decisions thereafter are
made autonomously with careful thought.19 In the case of
HPV-related cancers, interventions are not based on the
outcome of testing; thus, the situations are distinct. How-
ever, the approach to the process itself applies directly.
An example of prognostic information that does not
affect management exists with regard to Huntington
disease, an autosomal dominant, progressive neurologic
disease without any definitive treatment for which genetic
testing is possible for asymptomatic relatives of affected
patients. There is a wealth of information specific to this
field. Most ethicists agree that patients, equipped with the
appropriate medical knowledge, have the right to obtain
the results of genetic tests for the disease.20 Our current
discussion has similarities to the ethical issues in Hunting-
ton disease; both involve disclosure of prognostic infor-
mation without the availability of interventions
dependent on the outcome of testing. Of course, there are
significant differences in magnitude and outcome; Hun-
tington disease has a devastating clinical course, whereas
knowledge of HPV status modestly, and favorably, alters
the prognosis of a patient with a known diagnosis.
The prognostic value of HPV status with regard to
head and neck cancer is very different from other entities
such as breast cancer and Huntington disease, but certain
themes are shared. Patients require medical expertise to
understand the implications of their choices, but individ-
uals are ultimately allowed to make their own decisions.
Contemporary medical ethics shirks paternalism and the
concept of protecting patients from themselves. In gen-
eral, with regard to dilemmas in disseminating prognostic
information, the best solutions honor patient autonomy
and limit harm to others, while also ensuring that patients
are counseled appropriately both before and after testing
is performed.21 Thus, patients are privy to the knowledge
that HPV-related tumors may have a better than expected
outcome (and vice versa), despite the absence of any fur-
ther clinical measures resulting from this information.
The Case of HPV and Cervical Cancer
HPV is considered the causative agent in the majority of
cases of uterine cervical cancer, and this association is well
established. Taking into consideration the significant dif-
ferences between gynecologic and head and neck cancers,
we can use this model to guide our discussion. In most
cases, in contrast to HPV in head and neck cancer, HPV’s
role as a causative agent in cervical cancer is proven; thus,
a diagnostic dilemma is not much of a factor. In addition,
data suggest that persistent and recurrent infection is asso-
ciated with subsequent unprotected sexual encounters.22
For this reason, patient education encouraging safer sexual
Ethics of HPV and Head and Neck Cancer/Shuman and Wolf
Cancer September 15, 2010 4223
practices is not only valid from a public health standpoint,
but is actually designed to decrease the chances of recur-
rent neoplasm. In contrast, there are no data yet to suggest
that this is true for patients with HPV-related head and
neck cancer.
Although there is a stigma associated with sexually
transmitted infections, clinicians should not hesitate to
disclose clinical information (such as the existence of or
suspicion for HPV infection) to protect patients from
their own emotions. Tactful education and providing
resources for safer sexual practices are valuable interven-
tions, whether or not this decreases the likelihood of
recurrent cancer. In addition, taking a sexual history not
only assists with risk stratification, but will assist the clini-
cian in providing sound advice to patients regarding how
best to modify their risk for future exposure. These princi-
ples apply to patients with suspected HPV-related oro-
pharyngeal cancers as well as patients with cervical
neoplasms.
HPV Vaccination
The emergence of a multivalent HPV vaccine adds yet
another layer of complexity to this discussion. The ethics
of HPV vaccination has been previously reviewed con-
cerning adolescent girls and cervical cancer specifically,
and will not be discussed in detail here. The interested
reader is directed to excellent commentaries on the
topic.23,24 Generally speaking, the proponents of vaccina-
tion highlight the efficacy and safety of the vaccine and
the public health responsibility to protect citizens from
avoidable dangers, often citing the finding that other vac-
cines such as polio have been mandated with great suc-
cess.25 Opponents question the safety of the vaccine and
length of follow-up data in clinical trials, the need for a
vaccine given the availability of screening programs for
premalignant lesions, as well as the potential violation of
privacy, family values, and civil liberties.26 Some warn
that mandating vaccination is akin to ‘‘opening the flood
gates to governmental regulation of behavior in the name
of public health.’’27 Nevertheless, the majority of medical
societies support widespread vaccination.28
In theory, assuming an HPV vaccine is efficacious,
prevention of infection with high-risk HPV serotypes will
decrease the incidence of HPV-related head and neck
cancers.29 Unfortunately, given the latency between infec-
tion and neoplasm, and the generally low incidence of this
clinical entity (even when compared with cervical neo-
plasms), data confirming this hypothesis are many years
away.30 Thus, it is not justified to mandate vaccination of
all adolescents in an effort to prevent head and neck
cancer, as this outcome has not been clinically studied to
date. However, despite the dearth of data, the scientific
principle is sound. Although public health policy should
not be based solely on theory, physicians can certainly
advise their patients regarding the proven as well as the
potential benefits of a proposed intervention, so long as
the information is not misrepresented.
The other issue surrounding vaccination regards
whether men should be targeted. Men can develop HPV-
related genital and anal lesions, albeit with a considerably
lower incidence than cervical neoplasms in women. That
said, many women contract HPV from male sexual part-
ners, and the concept of herd immunity suggests that
decreasing the incidence of infection in the general popula-
tion will decrease the risk in those with a higher prevalence
of symptomatic disease, including sexually communicable
diseases.31 Moreover, men contract HPV-related head and
neck cancers with a similar incidence to women. Currently,
men are not targeted as candidates for vaccination, nor
have they been included in many of the clinical vaccine tri-
als to establish vaccine safety and efficacy.32 The US Food
and Drug Administration recently approved the vaccine
for males in order to prevent genital warts, with no men-
tion of the potential prevention of cancer-causing infec-
tions.33 Nonetheless, to decrease the risk of HPV-related
tumors, as well as to decrease the prevalence of HPV infec-
tion in the general population, vaccination of both sexes is
medically and epidemiologically sound.
On the basis of the potential advantages of male vac-
cination, from the standpoint of both herd immunity and
the theoretical prevention of head and neck cancer, fur-
ther studies and discussion of HPV vaccination in men
are warranted. Attitudes and education with regard to vac-
cination deserve mention. Men are generally uninformed
regarding the existence and consequences of HPV infec-
tion.34 Male attitudes toward HPV vaccination will need
to be clarified to tailor education and eventual vaccination
campaigns, as the direct benefits may be less apparent to
men than they are to women.35 The risk of HPV-related
head and neck cancer might assist in the education of both
sexes regarding risks, safer sexual practices, and the applic-
ability of vaccination.
Specific Recommendations
• To ensure that patients receive factual and accurate infor-
mation, HPV should be discussed as a possible etiologic
agent with all patients with oropharyngeal squamous cell
carcinoma.
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• Patient factors and physician judgment should dictate
the utility of discussing HPV in the setting of head and
neck cancers presenting at other head and neck sites in
which HPV is unlikely to be a causative factor.
• The transmissibility of HPV may be discussed at the dis-
cretion of physicians, acknowledging that other than
standard barrier methods, there exists no convincing evi-
dence that specific behavior modifications or sexual con-
tact precautions are necessary.
• The favorable prognosis of HPV-related neoplasms may
be discussed with patients as is clinically appropriate,
understanding that treatment is not currently adjusted
based on this information, and other factors can signifi-
cantly affect prognosis.
• Physicians may discuss the belief that HPV vaccination
theoretically might help prevent certain head and neck
cancers despite the absence of conclusive evidence.
Conclusions
Medicine is an imperfect science. The dynamic expansion
of scientific knowledge leaves rifts in our ability to effec-
tively counsel our patients. HPV-related head and neck
cancer is an emerging biologically distinct subset of head
and neck cancers for which best practice guidelines are far
from established. Patients deserve honesty, transparency,
and integrity with regard to information disseminated and
counseling provided, in the knowledge that the implica-
tions of this information may well change with the advent
of further scientific knowledge. Although a definitive deci-
sion-making algorithm does not yet exist, physicians and
patients should embark on a partnership in which the role
of HPV in head and neck cancer is shared and discussed.
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